We’re delighted to announce the start of an international research project under the European Consortium for Continuous Pharmaceutical Manufacturing (ECCPM). The collaborative efforts from industrial and scientific partners aim to develop continuous manufacturing practices and improve the quality and cost-effectiveness of nanoparticles-based drug products. Utilizing cutting-edge technology and innovative techniques, we’re paving the way for a new era of production and nanomedicine.
Skyepharma is already deeply involved in nanoparticles field with its NanoMicS program aiming at developing innovative nanoparticles-based oral formulations. Our participation in this Nanofact program will further accelerate this research program and will bring valuable knowledge on how to manufacture such complex formulations in a robust manner.